K. Lohmann

Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal

C. Sarrazin, C. Boesecke, C. Spinner, 2021, Health science reports.

Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R)

M. Cornberg, K. Simon, H. Klinker, 2022, Viruses.

The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real‐world data from the German Hepatitis C‐Registry (DHC‐R)

S. Mauss, P. Buggisch, M. Bondin, 2021, Journal of viral hepatitis.

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

P. Belperio, P. Lampertico, S. Mauss, 2020, Advances in Therapy.

Real‐world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C‐Registry

T. Berg, C. Niederau, S. Mauss, 2019, Alimentary pharmacology & therapeutics.

Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C‐Registry

T. Berg, S. Zeuzem, M. Rössle, 2021, Liver international : official journal of the International Association for the Study of the Liver.

Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real‐world data from the German Hepatitis C‐Registry

S. Mauss, H. Wedemeyer, T. Zimmermann, 2021, Liver international : official journal of the International Association for the Study of the Liver.